Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has successfully completed its planned public offering, issuing over 8 million shares at C$4.10 each for total proceeds of approximately C$33.9 million. These funds are earmarked for research and development, general corporate expenses, and working capital. The offering, which excluded Quebec, was managed by Raymond James Ltd. as the sole underwriter and bookrunner.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
